Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

被引：5
作者：
Abdelrahman, Aly M. [1 ]
Awad, Alaa S. [2 ]
Abdel-Rahman, Emaad M. [3 ]
机构：
[1] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Pharmacol & Clin Pharm, Al Khoud 123, Oman
[2] Univ Florida, Div Nephrol, Jacksonville, FL 32209 USA
[3] Univ Virginia, Div Nephrol, Charlottesville, VA 22908 USA
来源：
JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 04期
关键词：
SGLT2i; non-diabetics; CKD; blood pressure; IgAN; FSGS; proteinuria; survival; SGLT2; INHIBITORS; DIABETES-MELLITUS; DAPAGLIFLOZIN; METAANALYSIS; PROTEINURIA;
D O I：
10.3390/jcm13040956
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.
引用
收藏
页数：15
相关论文
共 88 条
[1]   Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice [J].
Abdelrahman, Aly M. ;
Al Suleimani, Yousuf ;
Shalaby, Asem ;
Ashique, Mohammed ;
Manoj, Priyadarsini ;
Nemmar, Abderrahim ;
Ali, Badreldin H. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 (01) :45-53
[2]   Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats [J].
Ala, Moein ;
Khoshdel, Mohammad Reza Fallahpour ;
Dehpour, Ahmad Reza .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
[3]  
Ali Badreldin H, 2019, Cell Physiol Biochem, V52, P27, DOI [10.33594/000000003, 10.33594/000000003]
[4]   Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial [J].
Anker, Stefan D. ;
Butler, Javed ;
Filippatos, Gerasimos ;
Khan, Muhammad Shahzeb ;
Marx, Nikolaus ;
Lam, Carolyn S. P. ;
Schnaidt, Sven ;
Ofstad, Anne Pernille ;
Brueckmann, Martina ;
Jamal, Waheed ;
Bocchi, Edimar A. ;
Ponikowski, Piotr ;
Perrone, Sergio, V ;
Januzzi, James L. ;
Verma, Subodh ;
Boehm, Michael ;
Ferreira, Joao Pedro ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton .
CIRCULATION, 2021, 143 (04) :337-349
[5]  
Awad AK, 2022, EUR HEART J, V43, P941
[6]   Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis [J].
Baker, William L. ;
Buckley, Leo F. ;
Kelly, Michael S. ;
Bucheit, John D. ;
Parod, Eric D. ;
Brown, Roy ;
Carbone, Salvatore ;
Abbate, Antonio ;
Dixon, Dave L. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (05)
[7]   Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus [J].
Bays, Harold E. ;
Weinstein, Richard ;
Law, Gordon ;
Canovatchel, William .
OBESITY, 2014, 22 (04) :1042-1049
[8]   Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study [J].
Boeckhaus, Jan ;
Gross, Oliver .
CELLS, 2021, 10 (07) :nas
[9]   SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy [J].
Cassis, Paola ;
Locatelli, Monica ;
Cerullo, Domenico ;
Corna, Daniela ;
Buelli, Simona ;
Zanchi, Cristina ;
Villa, Sebastian ;
Morigi, Marina ;
Remuzzi, Giuseppe ;
Benigni, Ariela ;
Zoja, Carlamaria .
JCI INSIGHT, 2018, 3 (15)
[10]   Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy [J].
Castoldi, Giovanna ;
Carletti, Raffaella ;
Ippolito, Silvia ;
Colzani, Massimiliano ;
Barzaghi, Francesca ;
Stella, Andrea ;
Zerbini, Gianpaolo ;
Perseghin, Gianluca ;
Zatti, Giovanni ;
di Gioia, Cira R. T. .
ACTA DIABETOLOGICA, 2021, 58 (08) :1059-1070
123456789